Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy Schmidt, Rafael Fonseca, Rajshekhar Chakraborty, Kelly Ann Koehn, Meera Mohan, Hira Mian, Luciano J. Costa, Douglas Sborov, Ghulam Rehman Mohyuddin

Research output: Contribution to journalArticlepeer-review

Abstract

Extra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1q, and its prognostic implications in MM randomized controlled trials (RCTs). Pubmed, Embase and Cochrane Registry of RCTs were searched from January 2012 to December 2022. Only MM RCTs were included. A total of 124 RCTs were included, of which 29 (23%) studies reported on +1q. Among them, 10% defined thresholds for +1q, 14% reported survival data separately for gain and amp, and 79% considered +1q a high-risk cytogenetic abnormality. Amongst RCTs that met the primary endpoint showing improvement in progression free survival (PFS), lenalidomide maintenance (Myeloma XI), selinexor (BOSTON), and isatuximab (IKEMA and ICARIA) were shown to improve PFS for patients with evidence of +1q. Some additional RCT’s such as Myeloma XI+ (carfilzomib), ELOQUENT-3 (elotuzumab), and HOVON-65/GMMG-HD4 (bortezomib) met their endpoint showing improvement in PFS and also showed improvement in PFS in the +1q cohort, although the confidence interval crossed 1. All six studies that reported HR for +1q patients vs. without (across both arms) showed worse OS and PFS for +1q. There is considerable heterogeneity in the reporting of +1q. All interventions that have shown to be successful in RCTs and have clearly reported on the +1q subgroup have shown concordant direction of results and benefit of the applied intervention. A more standardized approach to reporting this abnormality is needed.

Original languageEnglish (US)
Article number20
JournalBlood cancer journal
Volume14
Issue number1
DOIs
StatePublished - Dec 2024

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review'. Together they form a unique fingerprint.

Cite this